白三烯受体拮抗剂研究新进展  

Advances on leukotrienes and leukotriene receptor antagonists in asthma

作　　者：徐圣葆[1] 梅晓冬[1] 

机构地区：[1]安徽医科大学附属省立医院呼吸内科,安徽合肥230001

出　　处：《安徽医药》2007年第12期1057-1059,共3页Anhui Medical and Pharmaceutical Journal

摘　　要：白三烯(leukotrienes,LTs)是花生四烯酸的代谢产物之一,是白细胞重要的趋化剂和激动剂,是哮喘发病机制中最重要的炎症介质之一。可引起气道平滑肌收缩,增加血管通透性,增加黏液分泌,促进炎症细胞如嗜酸性粒细胞在气道的聚集,并能促进气道结构细胞的增殖从而参与气道重塑。白三烯受体拮抗剂能在一定程度上影响和克服这些病理生理变化,从而达到控制哮喘的目的,其在哮喘治疗中的作用日益受到人们重视。本文综述白三烯在哮喘发病机制中的作用和有关受体拮抗剂的新进展。Leukotrien, a metabolic product of arachinoid acid,is considered one of the most important inflammatory mediators involved in the mechanism of asthma. It confers to airway smooth muscle spasm, increases blood vessel permeability, promotes mucus excretion, enhances aggregation of inflammatory cells such as eosinophils in airway, promotes the proliferation of airway cells and is involved in the airway re-modeling. Leukotrien receptor antagonists could block these changes, The recent advances in the mechanisms of leukotriene and the leukotriene receptor antagonists in asthma are reviewed in this article.

关 键 词：白三烯 受体拈抗剂 支气管哮喘 

分 类 号：R562.25[医药卫生—呼吸系统]